Levobetaxolol

DB09351

small molecule approved investigational

Deskripsi

Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

Struktur Molekul 2D

Berat 307.434
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean half life of levobetaxolol is 20 h [FDA Label].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Levobetaxolol is applied topically to the eye but some does reach systemic circulaton with a Tmax of 3 h FDA Label.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1076 Data
Ceritinib Levobetaxolol may increase the bradycardic activities of Ceritinib.
Ivabradine Levobetaxolol may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Levobetaxolol.
Amiodarone The therapeutic efficacy of Levobetaxolol can be increased when used in combination with Amiodarone.
Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Levobetaxolol.
Dipyridamole Dipyridamole may increase the bradycardic activities of Levobetaxolol.
Disopyramide Disopyramide may increase the bradycardic activities of Levobetaxolol.
Dronedarone Dronedarone may increase the bradycardic activities of Levobetaxolol.
Fingolimod Levobetaxolol may increase the bradycardic activities of Fingolimod.
Floctafenine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Floctafenine.
Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Levobetaxolol.
Methacholine Levobetaxolol may increase the bronchoconstrictory activities of Methacholine.
Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Levobetaxolol.
Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Levobetaxolol.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Levobetaxolol.
Regorafenib Regorafenib may increase the bradycardic activities of Levobetaxolol.
Reserpine Reserpine may increase the hypotensive activities of Levobetaxolol.
Deserpidine Deserpidine may increase the hypotensive activities of Levobetaxolol.
Guanethidine Guanethidine may increase the hypotensive activities of Levobetaxolol.
Rivastigmine Levobetaxolol may increase the bradycardic activities of Rivastigmine.
Mirabegron The serum concentration of Levobetaxolol can be increased when it is combined with Mirabegron.
Insulin argine Levobetaxolol may increase the hypoglycemic activities of Insulin argine.
Nicotine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Nicotine.
Cevimeline The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Cevimeline.
Carbamoylcholine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Carbamoylcholine.
Bethanechol The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Bethanechol.
Pilocarpine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Pilocarpine.
Varenicline The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Varenicline.
Acetylcholine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Acetylcholine.
Arecoline The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Arecoline.
Lobeline The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Lobeline.
NGX267 The risk or severity of adverse effects can be increased when Levobetaxolol is combined with NGX267.
GTS-21 The risk or severity of adverse effects can be increased when Levobetaxolol is combined with GTS-21.
Epibatidine The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Epibatidine.
Xanomeline The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Xanomeline.
Thiethylperazine The serum concentration of Levobetaxolol can be increased when it is combined with Thiethylperazine.
Promazine The serum concentration of Levobetaxolol can be increased when it is combined with Promazine.
Prochlorperazine The serum concentration of Levobetaxolol can be increased when it is combined with Prochlorperazine.
Triflupromazine The serum concentration of Levobetaxolol can be increased when it is combined with Triflupromazine.
Fluphenazine The serum concentration of Levobetaxolol can be increased when it is combined with Fluphenazine.
Moricizine The serum concentration of Levobetaxolol can be increased when it is combined with Moricizine.
Trifluoperazine The serum concentration of Levobetaxolol can be increased when it is combined with Trifluoperazine.
Perphenazine The serum concentration of Levobetaxolol can be increased when it is combined with Perphenazine.
Mesoridazine The serum concentration of Levobetaxolol can be increased when it is combined with Mesoridazine.
Acetophenazine The serum concentration of Levobetaxolol can be increased when it is combined with Acetophenazine.
Promethazine The serum concentration of Levobetaxolol can be increased when it is combined with Promethazine.
Alimemazine The serum concentration of Levobetaxolol can be increased when it is combined with Alimemazine.
Periciazine The serum concentration of Levobetaxolol can be increased when it is combined with Periciazine.
Acepromazine The serum concentration of Levobetaxolol can be increased when it is combined with Acepromazine.
Aceprometazine The serum concentration of Levobetaxolol can be increased when it is combined with Aceprometazine.
Pipotiazine The serum concentration of Levobetaxolol can be increased when it is combined with Pipotiazine.
Thioproperazine The serum concentration of Levobetaxolol can be increased when it is combined with Thioproperazine.
BL-1020 The serum concentration of Levobetaxolol can be increased when it is combined with BL-1020.
Cyamemazine The serum concentration of Levobetaxolol can be increased when it is combined with Cyamemazine.
Methylene blue The serum concentration of Levobetaxolol can be increased when it is combined with Methylene blue.
Propiopromazine The serum concentration of Levobetaxolol can be increased when it is combined with Propiopromazine.
Perazine The serum concentration of Levobetaxolol can be increased when it is combined with Perazine.
Butaperazine The serum concentration of Levobetaxolol can be increased when it is combined with Butaperazine.
Chlorproethazine The serum concentration of Levobetaxolol can be increased when it is combined with Chlorproethazine.
Thiazinam The serum concentration of Levobetaxolol can be increased when it is combined with Thiazinam.
Dixyrazine The serum concentration of Levobetaxolol can be increased when it is combined with Dixyrazine.
Perphenazine enanthate The serum concentration of Levobetaxolol can be increased when it is combined with Perphenazine enanthate.
Digoxin Levobetaxolol may increase the bradycardic activities of Digoxin.
Acetyldigitoxin Levobetaxolol may increase the bradycardic activities of Acetyldigitoxin.
Deslanoside Levobetaxolol may increase the bradycardic activities of Deslanoside.
Ouabain Levobetaxolol may increase the bradycardic activities of Ouabain.
Digitoxin Levobetaxolol may increase the bradycardic activities of Digitoxin.
Oleandrin Levobetaxolol may increase the bradycardic activities of Oleandrin.
Cymarin Levobetaxolol may increase the bradycardic activities of Cymarin.
Proscillaridin Levobetaxolol may increase the bradycardic activities of Proscillaridin.
Metildigoxin Levobetaxolol may increase the bradycardic activities of Metildigoxin.
Lanatoside C Levobetaxolol may increase the bradycardic activities of Lanatoside C.
Gitoformate Levobetaxolol may increase the bradycardic activities of Gitoformate.
Acetyldigoxin Levobetaxolol may increase the bradycardic activities of Acetyldigoxin.
Peruvoside Levobetaxolol may increase the bradycardic activities of Peruvoside.
Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Levobetaxolol.
Icosapent Icosapent may decrease the antihypertensive activities of Levobetaxolol.
Mesalazine The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Levobetaxolol.
Indomethacin Indomethacin may decrease the antihypertensive activities of Levobetaxolol.
Nabumetone Nabumetone may decrease the antihypertensive activities of Levobetaxolol.
Ketorolac Ketorolac may decrease the antihypertensive activities of Levobetaxolol.
Tenoxicam Tenoxicam may decrease the antihypertensive activities of Levobetaxolol.
Celecoxib Celecoxib may decrease the antihypertensive activities of Levobetaxolol.
Tolmetin Tolmetin may decrease the antihypertensive activities of Levobetaxolol.
Rofecoxib Rofecoxib may decrease the antihypertensive activities of Levobetaxolol.
Piroxicam Piroxicam may decrease the antihypertensive activities of Levobetaxolol.
Fenoprofen Fenoprofen may decrease the antihypertensive activities of Levobetaxolol.
Valdecoxib Valdecoxib may decrease the antihypertensive activities of Levobetaxolol.
Diclofenac Diclofenac may decrease the antihypertensive activities of Levobetaxolol.
Sulindac Sulindac may decrease the antihypertensive activities of Levobetaxolol.
Flurbiprofen Flurbiprofen may decrease the antihypertensive activities of Levobetaxolol.
Etodolac Etodolac may decrease the antihypertensive activities of Levobetaxolol.
Mefenamic acid Mefenamic acid may decrease the antihypertensive activities of Levobetaxolol.
Naproxen Naproxen may decrease the antihypertensive activities of Levobetaxolol.
Sulfasalazine Sulfasalazine may decrease the antihypertensive activities of Levobetaxolol.
Phenylbutazone Phenylbutazone may decrease the antihypertensive activities of Levobetaxolol.
Meloxicam Meloxicam may decrease the antihypertensive activities of Levobetaxolol.
Carprofen Carprofen may decrease the antihypertensive activities of Levobetaxolol.
Diflunisal Diflunisal may decrease the antihypertensive activities of Levobetaxolol.
Salicylic acid Salicylic acid may decrease the antihypertensive activities of Levobetaxolol.

Target Protein

Beta-1 adrenergic receptor ADRB1

Referensi & Sumber

Textbook
  • ISBN: 9780071624428
    Goodman, Louis Sanford, Brunton, Laurence L. Chabner, Bruce. Knollman, Bjorn C. (2011). Goodman and Gilman's the pharmacological basis of therapeutics, Pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul